Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Bisphosphonate

Therapeutic area intelligence for Bisphosphonate with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 0
Companies: 5

Companies

Aurobindo Pharma →

IPCA Labs Ltd. →

Assets

Recent signals(8)

RegulatoryAugust 4, 2026

FDA accepts supplemental application for Alendronate Sodium by Apotex

The FDA has accepted a supplemental application for Alendronate Sodium submitted by Apotex.

RegulatoryJuly 29, 2026

FDA Approval Process Update for Alendronate Sodium by Impax Labs

The FDA has an active application (ANDA075710) for Alendronate Sodium submitted by Impax Labs, currently under standard review.

StrategyJuly 27, 2026

Aurobindo Pharma's Alendronate Sodium Supplement Application Approved by FDA

The FDA has approved the supplemental application ANDA090124 for Alendronate Sodium submitted by Aurobindo Pharma.

StrategyJuly 26, 2026

FDA Grants AP Status for Alendronate Sodium ANDA206387 by IPCA Labs

The FDA has granted approval status (AP) for the ANDA206387 application for Alendronate Sodium submitted by IPCA Labs.

RegulatoryJuly 13, 2026

FDA Approves Supplement for Alendronate Sodium by Rising

The FDA has approved a supplemental application for Alendronate Sodium submitted by Rising.

StrategyJuly 3, 2026

FDA Grants AP Status for Alendronate Sodium ANDA206387

The FDA has granted approval status (AP) for the ANDA206387 application for Alendronate Sodium submitted by IPCA Labs Ltd.

RegulatoryJune 23, 2026

FDA Grants AP Status for Teva's Risedronate Sodium Supplement

Teva Pharmaceuticals has received an Abbreviated Approval (AP) for a supplement of Risedronate Sodium.

StrategyJune 23, 2026

Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status

Aurobindo Pharma's ANDA for Risendronate Sodium has been granted Abbreviated Approval (AP) status by the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.